Editing Stem Cells to Change the Course of Disease
Sickle cell disease is an inherited blood disorder that causes red blood cells to become rigid and misshapen. These abnormal cells can block blood flow, leading to painful episodes known as vaso-occlusive crises, along with anemia and damage to organs over time.
A Phase 3 clinical trial explored a very different type of treatment: using a patient’s own blood-forming stem cells, editing them with CRISPR-Cas9, and returning them to the body.
The treatment, called exagamglogene autotemcel (exa-cel), is designed to help the body produce more fetal hemoglobin, a form of hemoglobin that can reduce the damaging effects of sickle hemoglobin.
How Does the Treatment Work?
Researchers first collected CD34+ hematopoietic stem and progenitor cells from each patient. These cells are responsible for producing the different types of blood cells found throughout the body.
The cells were then edited outside the body using CRISPR-Cas9 technology. Rather than directly correcting the sickle cell mutation, the treatment targets a genetic switch that normally reduces fetal hemoglobin production after birth.
After receiving intensive conditioning treatment to prepare the bone marrow, patients were infused with their own edited cells.
Putting Exa-Cel to the Test
The study included patients between 12 and 35 years old who had severe sickle cell disease and a history of frequent painful crises. A total of 44 patients received exa-cel and were followed for a median of about 19 months.
The main question researchers wanted to answer was whether patients could remain free from severe vaso-occlusive crises for at least 12 consecutive months.
A Major Reduction in Pain Crises
The results were striking. Among the 30 patients who had enough follow-up time to be fully evaluated, 29 of them, or 97%, experienced no severe vaso-occlusive crises for at least 12 consecutive months. Even more encouraging, all 30 patients avoided hospitalization for severe vaso-occlusive crises for at least 12 months.
Researchers also observed sustained increases in fetal hemoglobin and overall hemoglobin levels, along with improvements in several markers related to red blood cell breakdown.
What About Safety?
All patients successfully regained neutrophils and platelets after treatment, showing that the edited stem cells were able to establish themselves and begin producing blood cells.
Most side effects were consistent with what researchers would expect from the intensive chemotherapy-like conditioning needed before an autologous stem cell transplant. Importantly, no cancers were reported during the study period.
However, this is still an intensive treatment process. Patients must undergo stem cell collection, laboratory gene editing, strong conditioning therapy, and hospitalization, so the procedure is very different from a routine infusion or injection.
Why Is This Study So Important?
One of the most interesting parts of this research is that it addresses sickle cell disease at a very early biological level. Instead of repeatedly treating pain crises after they occur, exa-cel aims to change how a patient’s own blood-forming stem cells produce hemoglobin.
The edited stem cells can continue producing new blood cells, which means the treatment is designed to create a lasting biological effect from a single treatment process.
A New Direction for Regenerative and Genetic Medicine
The study was not randomized and did not include a placebo group, so continued long-term follow-up remains important. Researchers are also monitoring participants for years to better understand the durability and long-term safety of the gene editing.
Still, the results represent a major step forward. Nearly all evaluable participants remained free from severe pain crises for at least a year, while all avoided hospitalization for these events during that period.
This study highlights how regenerative medicine and gene editing can work together, using a patient’s own stem cells not only to replace blood-forming cells, but to change how those cells function before they are returned to the body.
Source
Frangoul H, Locatelli F, Sharma A, et al. Exagamglogene Autotemcel for Severe Sickle Cell Disease. New England Journal of Medicine. 2024;390:1649-1662. doi: 10.1056/NEJMoa2309676. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2309676
Related Treatment Pages